Novel coronavirus – SARS CoV-2
DOI:
https://doi.org/10.2478/pjph-2019-0026Keywords:
coronaviruses, SARS CoV-2, epidemiology, therapy, vaccineAbstract
Coronaviruses cause a variety of diseases in mammals and birds. In late December, 2019, patients presenting with viral pneumonia due to an unidentified microbial agent were reported in Wuhan, China. A novel coronavirus was subsequently identified as the causative pathogen, provisionally named 2019 novel coronavirus (2019-nCoV). This virus appears to be a new human pathogen. In this article the biology of virus has been described, replication cycle and epidemiology of COVID 19. The next part discusses current methods of laboratory diagnostics. The coronavirus disease 2019 (COVID-19) pandemic has focused attention on the need to develop effective therapies against the causative agent, SARS-CoV-2. Researchers are therefore focusing on steps in the CoV replication cycle that may be target to inhibition by broad-spectrum or specific antiviral agents. Many laboratories focus on vaccine development. SARS-CoV-2 vaccines will be essential to reduce morbidity and mortality if the virus establishes itself in the human population. Novel coronavirus – SARS CoV-2
References
1. Kahn JS, McIntosh K. History and recent advances in coronavirus discovery. Pediatr Infect Dis. 2005;24:223-7.
2. Zhong N, Zheng BY, Li Y, et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong. People’s Republic of China, in February, 2003. Lancet. 2003;362(9393):1353-8.
3. Wang N, Shi L, Zhang S, et al. Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res. 2013;23:986-90.
4. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565-74.
5. Lauring AS, Andino R. Quasispecies theory and the behavior of RNA viruses. PLoS Pathog. 2010;6:e1001005.
6. Shereen A, Khan S, Kazmi A, et al. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. J Advanc Res. 2020;24:91-8.
7. Ashour H, Elkhatib W, Rahman M, et al. Insights into the Recent 2019 Novel Coronavirus (SARS-CoV-2) in Light of Past Human Coronavirus Outbreaks. Pathogens. 2020;9:186.
8. Fung TS, Liu DX. Human coronavirus: host-pathogen interaction. Annu Rev Microbiol. 2019;73:529-57.
9. Lin X, Gong Z, Xiao Z, et al. Novel coronavirus pneumonia outbreak in 2019: Computed tomographic findings in two cases. Korean J Radiol. 2020;21(3):365-8.
10. Velavan TP, Meyer C. The Covid-19 epidemic. Tropical Med Int Health 2020;25(3):278-80.
11. Zhu, N, Zhang D, Wang, et al. Investigating, China Novel Coronavirus, 2019. Research Team. A novel coronavirus from patients with pneumonia in China. N Engl J Med. 2020;382(8):727-33.
12. Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl Med. 2020; 382:1708-20.
13. Definicja przypadku na potrzeby nadzoru nad zakażeniami ludzi nowym koronawirusem SARS-CoV-2. GIS; www.gis.gov.pl.
14. Phan T. Novel coronavirus: from discovery to clinical diagnostics. Infect. Genet Evol. 2020;79;104211.
15. Nishiura H, Linton NM, Akhmetzhanov AR. Initial cluster of novel coronavirus (2019-nCoV) infections in Wuhan, China is consistent with substantial human-to-human transmission. J Clin Med. 2020;9(2):488.
16. Yu F, Du L, Ojcius DM, Pan C, Jiang S. Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China. Microbes Infect. 2020;22(2):74-9.
17. Loeffelholz MJ, Tang YW. Laboratory diagnosis of emerging human coronavirus infections – the state of the art. Emerg Microbes Infect. 2020;9(1):747-56.
18. Guangdi L, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020;19:149-50.
19. Wu C, Liu Y, Yang, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. APSB. 2020;10(5):766-88.
20. Wang, M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269-71.
21. Solidarity clinical trial for COVID-19 treatments. WHO, www.who.int.
22. Amant F, Krammer F, SARS CoV-2 Vaccines: Status Report. Immunity 2020; doi: 10.1016/j.immuni.2020.03.007 [Epub ahead of print].
23. Phan T. Genetic diversity and evolution of SARS-CoV-2. Infect Genet Evol. 2020;81:104260.
24. Morais IJ Jr, Polveiro RC, Souza GM, et al. The global population of SARS-CoV-2 is composed of six major subtypes. bioRxiv. https://doi.org/10.1101/ 2020.04.14.040782.
25. Pachetti M, Marini B, Benedetti F, et al. Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant. J Transl Med. 2020;18:179.
Downloads
Published
Issue
Section
License
Copyright (c) 2020 Polish Journal of Public Health
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
